200 related articles for article (PubMed ID: 21498100)
21. Insulin-like growth factor I (IGF-I) replacement during growth hormone receptor antagonism normalizes serum IGF-binding protein-3 and markers of bone formation in ovariectomized rhesus monkeys.
Wilson ME
J Clin Endocrinol Metab; 2000 Apr; 85(4):1557-62. PubMed ID: 10770197
[TBL] [Abstract][Full Text] [Related]
22. Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I.
Lemmey AB; Glassford J; Flick-Smith HC; Holly JM; Pell JM
J Endocrinol; 1997 Aug; 154(2):319-28. PubMed ID: 9291843
[TBL] [Abstract][Full Text] [Related]
23. GH strongly affects serum concentrations of mannan-binding lectin: evidence for a new IGF-I independent immunomodulatory effect of GH.
Hansen TK; Thiel S; Dall R; Rosenfalck AM; Trainer P; Flyvbjerg A; Jørgensen JO; Christiansen JS
J Clin Endocrinol Metab; 2001 Nov; 86(11):5383-8. PubMed ID: 11701711
[TBL] [Abstract][Full Text] [Related]
24. Leucine supplementation improves acquired growth hormone resistance in rats with protein-energy malnutrition.
Gao X; Tian F; Wang X; Zhao J; Wan X; Zhang L; Wu C; Li N; Li J
PLoS One; 2015; 10(4):e0125023. PubMed ID: 25909895
[TBL] [Abstract][Full Text] [Related]
25. Regulation of the growth hormone-insulin-like growth factor I axis in developing and adult monkeys is affected by estradiol replacement and supplementation with insulin-like growth factor I.
Wilson ME
J Clin Endocrinol Metab; 1998 Jun; 83(6):2018-28. PubMed ID: 9626134
[TBL] [Abstract][Full Text] [Related]
26. Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist.
Andreassen M; Frystyk J; Faber J; Kristensen LØ; Juul A
Andrology; 2013 Jul; 1(4):595-601. PubMed ID: 23785020
[TBL] [Abstract][Full Text] [Related]
27. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth.
Divisova J; Kuiatse I; Lazard Z; Weiss H; Vreeland F; Hadsell DL; Schiff R; Osborne CK; Lee AV
Breast Cancer Res Treat; 2006 Aug; 98(3):315-27. PubMed ID: 16541323
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
Jensen PB; Hansen TB; Frystyk J; Ladefoged SD; Pedersen FB; Christiansen JS
Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
30. Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.
Muller AF; Leebeek FW; Janssen JA; Lamberts SW; Hofland L; van der Lely AJ
J Clin Endocrinol Metab; 2001 Nov; 86(11):5165-71. PubMed ID: 11701672
[TBL] [Abstract][Full Text] [Related]
31. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
[TBL] [Abstract][Full Text] [Related]
32. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
33. Growth hormone receptor antagonist treatment reduces exercise performance in young males.
Goto K; Doessing S; Nielsen RH; Flyvbjerg A; Kjaer M
J Clin Endocrinol Metab; 2009 Sep; 94(9):3265-72. PubMed ID: 19549743
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
35. Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats.
Grøfte T; Wolthers T; Jensen SA; Møller N; Jørgensen JO; Tygstrup N; Orskov H; Vilstrup H
Hepatology; 1997 Apr; 25(4):964-9. PubMed ID: 9096605
[TBL] [Abstract][Full Text] [Related]
36. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans.
Olivecrona H; Hilding A; Ekström C; Barle H; Nyberg B; Möller C; Delhanty PJ; Baxter RC; Angelin B; Ekström TJ; Tally M
J Clin Endocrinol Metab; 1999 Feb; 84(2):553-60. PubMed ID: 10022415
[TBL] [Abstract][Full Text] [Related]
37. Administration of growth hormone and nandrolone decanoate alters mRNA expression of the GABAB receptor subunits as well as of the GH receptor, IGF-1, and IGF-2 in rat brain.
Grönbladh A; Johansson J; Nyberg F; Hallberg M
Growth Horm IGF Res; 2014; 24(2-3):60-6. PubMed ID: 24480470
[TBL] [Abstract][Full Text] [Related]
38. Effects of dietary supplementation with cysteamine on growth hormone receptor and insulin-like growth factor system in finishing pigs.
Liu G; Wei Y; Wang Z; Wu D; Zhou A
J Agric Food Chem; 2008 Jul; 56(13):5422-7. PubMed ID: 18553891
[TBL] [Abstract][Full Text] [Related]
39. Muscle mechano growth factor is preferentially induced by growth hormone in growth hormone-deficient lit/lit mice.
Iida K; Itoh E; Kim DS; del Rincon JP; Coschigano KT; Kopchick JJ; Thorner MO
J Physiol; 2004 Oct; 560(Pt 2):341-9. PubMed ID: 15308683
[TBL] [Abstract][Full Text] [Related]
40. Effects of GH and/or sex steroids on circulating IGF-I and IGFBPs in healthy, aged women and men.
Münzer T; Rosen CJ; Harman SM; Pabst KM; St Clair C; Sorkin JD; Blackman MR
Am J Physiol Endocrinol Metab; 2006 May; 290(5):E1006-13. PubMed ID: 16390864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
